(Total Views: 385)
Posted On: 04/15/2020 9:37:25 PM
Post# of 36566
Re: homerbedloe #15243
Maybe no one knows who NuGenerex Immuno-Oncology is? I know they are trying to position the name, but they should at least say NGIO, subsidiary of Generex Biotechnology.
“On a FiercePharma virtual panel last month, NuGenerex Immuno-Oncology chief scientific officer Eric von Hofe said it’s “not at all unlikely” the world could see multiple vaccines approved.
“By definition, a pandemic spans multiple different regulatory jurisdictions,” he said. “A lot of different countries are going to have their own approach in terms of what they want to see in a vaccine.”
As the process plays out, experts are “going to be getting a lot of new information” about how the various vaccines stack up, he said, which will guide regulatory decisions. “
“On a FiercePharma virtual panel last month, NuGenerex Immuno-Oncology chief scientific officer Eric von Hofe said it’s “not at all unlikely” the world could see multiple vaccines approved.
“By definition, a pandemic spans multiple different regulatory jurisdictions,” he said. “A lot of different countries are going to have their own approach in terms of what they want to see in a vaccine.”
As the process plays out, experts are “going to be getting a lot of new information” about how the various vaccines stack up, he said, which will guide regulatory decisions. “
(0)
(0)
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
